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Summary: Fifty adults hospitalized with extensive burns formed the basis of the present study. Serum amyloid A
protein, C-reactive protein, arantichymotrypsm and aracid glycoprotein were measured in serum samples taken
on admission, and 3 and 7 days later. Fatal outcome was observed in 13 out of 14 (93%) patients with serum
amyloid A protein over 100 mg/1 on admission and in only 2 of the remaining 36 (6%) patients with serum amyloid
A protein below 100 mg/1. The median serum amyloid A protein concentration on admission in 15 patients with
fatal outcome was 134 mg/1, and only 30 mg/1 in 35 patients who recovered (p < 0.00005). As a reference value,
the level of 100mg serum amyloid A protein per litre on admission gave an evident predictive value (93%)
and sensitivity (87%) for fatal outcome. The difference between serum amyloid A protein concentrations in
patients with complications (median 642 mg/1) and those without complications (median 250 mg/1) was statistic-
ally very significant (p = 0.0003) three days after burn injury. The level of 400 mg/1 as a reference value 3
days after burn injury gave a reasonable predictive value (80%) and sensitivity (74%) for the development of
postburn complications, but patients who died did not develop a hypermetabolic reaction and their serum
amyloid A protein concentration remained below 400 mg/1, despite high serum amyloid A protein concentrations
observed on admission (above 100 mg/1). No statistical significance was observed for the other 3 acute phase
proteins investigated in this study.
Introduction
Thermal injury is caused by overheating of body
tissues above the critical temperature, leading to tissue
damage. The pathophysiology of the burn syndrome
is characterized by the burn wound, its infection and
the host's impaired defence to it, hypermetabolism
and increased energy demand. Vital postburn compli-
cations are: pulmonary insufficiency, renal insuffi-
ciency and complications involving the gastrointestinal
tract (1).
Tissue damage, including burns, leads to considerable
changes in plasma proteins, a reaction commonly re-
ferred to as "the acute phase response". The concentra-
tion of many plasma proteins, derived largely from the
liver, changes during inflammation. These are known as
acute phase proteins. Severely burned patients display a
strong acute phase response in the first hours to days
after burn injury. They often have a high fever within
24 hours and produce acute phase proteins (2). A reli-
able marker of acute phase response must fulfill the
following criteria: a rapid and substantial increase in
concentration following an inflammatory stimulus and a
short half-life in circulation (3). Although some 34
known plasma proteins increase in concentration during
inflammation, only two of them are suitable markers of
acute phase response: serum amyloid A protein and C-
reactive protein (4—6). Both are quick to respond and
both increase substantially in severe inflammation, but
serum amyloid A protein is the more sensitive quantity
(6—9). It shows a more than 1000-fold increase in
plasma concentration a few hours (4—6) after inflamma-
tory stimulus (3), and has a very short half life of be-
tween 75 and 90 minutes (10, 11). Serum amyloid A
protein is an apolipoprotein of very low density (VLDL)
and high density lipoproteins (HDL) (12) and may have
an important role in the removal of excess cholesterol
from phagocytosing macrophages. It is probably a re-
cognition marker for liver uptake of HDL-bound choles-
terol, hence its clearance from the circulation (3). It has
been shown that serum amyloid A protein-enriched
HDL are catabolized more rapidly than normal HDL.
Possibly HDL and perhaps also VLDL may function to
remove non-polar toxins or cellular constituents from
sites of injury and transport them to the liver for detoxi-
fication (13).
The aim of the present study was to evaluate the behavi-
our of serum amyloid A protein together with the other
three most important acute phase proteins: C-reactive
protein, a!-antichymotrypsin and α\ -acid glycoprotein
in the early phases of severe burns, in order to determine
the statistical* significance of these biochemical indica-
tors for the early prediction of postburn complications
and fatal outcome.
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Patients and Methods
The study group comprised 50 adults (aged between 21 and 82
years, mean age 45) with total body surface area burns greater than
20% (range from 20 to 95%, mean 42%). All patients received a
uniform regime of treatment consisting of standard fluid resuscita-
tion, nutritional support, plasma expanders, fresh frozen plasma
and prophylactic antibiotic therapy. A topical antimicrobial agent,
silver sulfadiazine, was applied to delay the onset of and decrease
the level of bacterial colonization. The first blood samples were
taken immediately upon admission and subsequently on days 3 and
7 after the burn injury. Sera from patients who developed compli-
cations were taken every day during that period. Sera were stored
at -20 °C and assayed in batches at the end of the study. Serum
amyloid A protein concentrations were determined by the micro
ELISA test (14) with a sensitivity of 0.1 mg/1 and precision ex-
pressed as coefficients of variation between 1.6 and 4.2%. Immu-
noaifinity-purified sequence-specific antibody against serum amy-
loid A protein (15) was obtained from Tinolab (Zagreb, Coratia).
C-reactive protein, arantichymotrypsin and aracid glycoprotein
were determined by the method ofMancini et al. (16) with a sensi-
tivity of 5 mg/1 and coefficients of variation below 5%. Specific
antibodies against C-reactive protein were obtained from Roche
Diagnostica (Basel, Switzerland) while specific antibodies against
αι-anticliymotrypsin and α ι-acid glycoprotein, human serum C-re-
active protein calibrator and human serum protein calibrator (for
ctrantichymotrypsin and αϊ-acid glycoprotein standardization)
were purchased from Dako (Glostrup, Denmark). The statistical
significance was calculated using the Mann-Whitney U test.
Results
Figure 1 shows the changes of the median concentra-
tions of all four acute phase proteins during the course
of 7 days. Altogether 27 patients (54%) developed post-
burn complications and 15 patients (30%) had fatal out-
come. The average age of the survivors was 40 years,
and that of the non-survivors was 55 years. The survi-
vors had less severe burns, with a mean total body sur-
face area burn of 37%, while the non-survivors had a
mean total body surface area burn of 46%.
According to these findings, patients were divided into
two groups: survivors (35 patients) and non-survivors
(15 patients). The same patients were again divided into
1000-
Fig. 1 Seven days follow-up of: serum amyloid A protein (B), C-
reactive protein (o), (Xi-antichymotrypsin (Δ) and aracid glyco-
protein (^) concentrations in 50 patients with severe burns. Each
data point is the group median value. N denotes normal value.
two further groups: those who developed postburn com-
plications (27 patients) and those who did not (23 pa<-
tients). Results are presented in figure 2.
Fatal outcome was observed in 13 out of 14 (93%) pa-
tients with serum amyloid A protein concentrations
above 100 mg/1 on admission and in only 2 of the re-
maining 36 (6%) patients with serum amyloid A protein
concentrations below 100 mg/1. The median serum amy-
loid A protein concentration on admission in 15 patients
with fatal outcome was 134 mg/1 and only 30 mg/1 in
35 patients that recovered (p < 0.00005, U = 70); the
normal mean (reference) value for 30 healthy adults was
0.8 mg/1, range < 0.1 — 1.2 mg/1. The difference between
serum amyloid A protein concentrations in patients who
later developed complications (with median serum amy-
loid A protein value of 642 mg/1-on day 3 and 1050
mg/1 on day 7) and those who did not (with median
serum amyloid A protein value of 250 mg/1 on day 3
and 175 mg/1 on day 7) was statistically very significant
(p = 0.0003, U = 125 and p < 0.00005, U = 85, three
and seven days after burn injury, respectively).
Fatal outcome was observed in 9 out of 23 (39%) pa^
tients with C-reactive protein values above 10 mg/1 on
admission and in 6 out of the remaining 27 (22%) pa-
tients with C-reactive protein values below 10 mg/1. The
median C-reactive protein concentration on admission
in 15 patients with fatal outcome was 17 mg/1 and 9 mg/1
in 35 patients that recovered (p = 0.221, U = 205);
mean value of 30 healthy adults was below 5 mg/1.
There was no statistically significant difference on ad-
mission or three days later between C-reactive protein
values in patients who developed complications and
those who did not (median C-reactive protein values of
60 and 53 mg/1 on day 3, respectively), but it was very
high 7 days after burn injury (p < 0.00005, U = 82;
with median C-reactive protein values of 134 and 40
mg/1, respectively).
Fatal outcome was observed in 9 out of 21 (43%) pa-
tients with arantichymotiypsin values above 0.40 g/1 on
admission and in 6 out of remaining 29 (21%) patients
with arantichymotrypsin values below 0.40 g/1. The
median arantichymotrypsin value of admission in 15
patients with fatal outcome was 0.47 g/1 and 0.39 g/1 in
35 patients that recovered (p = 0.015, U = 180). There
was no statistically significant difference on admission
between arantichymotrypsin values in patients who de-
veloped complications and those who did not, but signif-
icant differences were observed 3 and 7 days after burn
injury (p = 0.0452, U = 203 and p = ΟΌ17, U = 181,
respectively).
Fatal outcome was observed in 10 out of 25 (40%) pa-
tients with aracid glycoprotein concentrations above
0.70 g/1 on admission and in 5 out of the remaining 25
(20%) patients with aracid glycoprotein values below
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0.70 g/l. The median αϊ-acid glycoprotein value on ad-
mission in 15 patients with fatal outcome was 0.76 g/1
and 0.70 g/1 in 35 patients that recovered, with no statis-
tically significant difference. There was also no statistic-
ally significant difference during the investigated period
between patients who developed complications and
those who did not.
There was no correlation among the concentrations of
acute phase proteins on admission or later.
Discussion
Our results show that severe burns induce a dramatic
acute phase response within the first hours of injury.
Peak levels of serum amyloid A protein and C-reactive
protein were increased up to 3000- and 100-fold above
normal concentrations, respectively. arAntichymotryp-
sin and αϊ-acid glycoprotein peak levels were increased
up to sixfold above their normal values. These findings
are very similar to our previous observations with acute
phase proteins in patients with acute myocardial infarc-
tion (8). On admission to hospital, the ratio between se-
rum amyloid A protein and C-reactive protein levels was
usually between 5 : 1 and 11:1, which is similar to
those observed during kidney allograft rejection (10 : 1)
(17-19), influenza (11:1) or pneumonia (7:1) (9). The
ratio between serum amyloid A protein and C-reactive
protein was more increased 7 days after burn injury, and
in same cases with postburn complications it was higher
than 30: 1, which we believe is the highest ratio ever
reported, although we measured higher individual serum
amyloid A protein concentrations in the sera of patients
with acute myocardial infarction (9). In patients who
developed postburn infections or sepsis, we found
higher serum amyloid A protein values and a higher se-
rum amyloid A protein/C-reactive protein ratio than we
had observed earlier in patients with urinary tract infec-
tions (5:1) (6) or in neutropenic patients with acute
leukaemia during their infectious febrile episodes ( 1 : 1
to 5 : 1) (7).
Results from this study suggest that postburn complica-
tions and fatal outcome are closey correlated with the
serum amyloid A protein values determined on admis-
sion and three days later. As a reference value, the level
of 100 mg/1 on admission gave an evident predictive
value (93%) and sensitivity (87%) for fatal outcome.
The level of 400 mg/1, as a reference value 3 days after
burn injury, gave a reasonable predictive value (80%)
and sensitivity (74%) for the development of postburn
complications. Patients who died did not develop a hyp-
ermetabolic reaction and their serum amyloid A protein
levels remained below 400 mg/1, despite high levels
(above 100 mg/1) on admission.
It was not possible to identify any C-reactive protein
level on admission or later which would give a reason-
able predictive value and sensitivity for mortality rate.
The best results on admission were obtained with a level
of 10 mg/1 but with a poor predictive value (39%) and
sensitivity (60%). Seven days later a level of 100 mg/1
as reference value gave a good sensitivity for mortality
t [d]
Fig. 2 Comparison among acute phase protein concentrations in complications (o) and patients who recovered without complica-
four groups of patients with severe bums: patients with fatal out- tions (o). Each data point is the group median value,
come (B) and survivors (D); patients who developed postburn







































Fig. 3 Multiple box-and-whisker plot for serum amyloid A pro-
tein and C-reactive protein values on admission. Group F = pa-
tients with fatal outcome; group R = patients who recovered (sur-
vivors).
Fig. 4 Multiple box-and-whisker plot for serum amyloid A pro-
tein and C-reactive protein values three days after admission.
Group C = patients who developed postburn complications; group
N = patients who did not develop postburn complications.
rate (11/15; 73%) with no predictive value (11/24; 46%)
but with a good predictive value (20/24; 83%) and sensi-
tivity (20/27; 74%) for developing postburn complica-
tions.
Similarly, it was not possible to identify an arantichy-
motrypsin level on admission or later which would give
a reasonable predictive value and sensitivity for mortal-
ity rate. The best results on admission were obtained
with a level of 0.40 g/1 but with a poor predictive value
(43%) and sensitivity (60%). As a reference value, 1.00
g/1 gave a good sensitivity for mortality rate (12/15;
80%) with no predictive value (12/27; 44%) but with a
poor predictive value and sensitivity (18/27; 67%) for
developing postburn complications.
There was no α ι -acid glycoprotein level on admission
or later which would give a reasonable predictive
value and sensitivity for mortality rate. The best re-
sults were obtained with a level of 0.70 g/1 on admis-
sion but with a poor sensitivity (67%) and no predic-
tive value (40%).
According to the results presented in this study, we con-
clude that serum amyloid A protein is the best of all the
four acute phase proteins investigated as a marker for
early prediction of postburn complications and fatal out-
come, even in the very early phase. Negligible overlap
of serum amyloid A protein data in multiple box-and-
whisker plots presented in figures 3 and 4 suggests that
serum amyloid A protein is a very useful clinical labora-
tory quantity for differentiating patients with severe
burns at the very beginning of the injury.
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